A Phase 1b, Single Dose, Open-Label, Dose-escalation Study to Investigate the Safety and Imaging Characteristics of LS301-IT for Intraoperative Imaging of Lung Cancer
Latest Information Update: 09 Dec 2024
Price :
$35 *
At a glance
- Drugs LS 301 IT (Primary)
- Indications Lung cancer
- Focus Adverse reactions
- Sponsors Integro Theranostics
- 09 Dec 2024 New trial record